ZK261991（ZK991）|DC Chemicals

ZK261991（ZK991）|DC Chemicals

ZK261991 is a highly selective and potent VEGFR-kinase inhibitor, which is orally available.

Product name: ZK261991(ZK991) |Cat No. DC8233|Other names: ZK-261991，ZK 261991，ZK-991，ZK 991|Cas: 886563-25-3|Molecule Weight: 443.5|Molecule Formular: C24H25N7O2| Purity: >98%

ZK261991 is a highly selective and potent VEGFR-kinase inhibitor, which is orally available. Kaplan-Meier analysis of survival showed a significant benefit for mice treated with ZK261991 after HPAF-2 tumor resection: 83.8 days (95% CI 73.9-93.6) vs. 60.9 days (95% CI 48.9-73.0), p = 0.006. Adjuvant treatment with ZK261991 of AsPC-1-derived tumors showed a tendency towards a benefit compared to control but no significant difference: 75.8 days (95% CI 59.7-91.9) vs. 65.7 days (95% CI 51.6-79.7). There were no significant differences in dissemination score and size of recurrent tumor mass between the treatment groups. Adjuvant anti-angiogenic therapy with the novel VEGFR-inhibitor ZK261991 resulted in a significant survival benefit after curative tumor resection in a clinically relevant orthotopic animal model of pancreatic cancer. Combination of anti-angiogenic treatment with cytotoxic agents may further improve the results of adjuvant therapy.

For research and scientific purpose only, not for human use.